Biotechnology News and Research

RSS

Daiichi Sankyo to deploy Veeva CRM for strengthening customer engagements in the UK

Veeva Systems announced today that Daiichi Sankyo, one of the world's top 20 pharmaceutical companies, is replacing its legacy, on-premise Customer Relationship Management (CRM) system with Veeva CRM in the UK.

26 Jul 2011

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, announced today that it has signed an agreement with PharmaNet LLC, an inVentiv Health Company, to assist in the development of the protocol and IND file for submission to the FDA for approval of BrainStorm's ALS human clinical trials in the United States.

26 Jul 2011

UC San Diego receives NHLBI 'Program of Excellence in Glycosciences' grant

Scientists at the University of California, San Diego School of Medicine have received a major 7-year, $18 million grant to begin translating emerging discoveries in the field of glycosciences into new discoveries and therapies related to heart, lung and blood diseases.

26 Jul 2011

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

26 Jul 2011

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

25 Jul 2011

Advanced Instruments launches Advanced Automated Osmometer

Advanced Instruments, Inc., today introduced the A2O Advanced Automated Osmometer, a multi-sample instrument that sets new benchmarks for analytical performance, ease of use, and true walk away operation capabilities in osmolality testing.

25 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

New WHO policy recommendation warns against use of blood tests for active TB

A new policy recommendation released on 20 July by the World Health Organization (WHO) warns against the use of serological (blood) tests to diagnose active tuberculosis.

25 Jul 2011

Sartorius sales revenue increases 12.2% to 353.7M euros in the first half of 2011

Sartorius, a leading international laboratory and process equipment provider, successfully closed the first half of 2011, with double-digit growth rates in sales revenue and earnings.

From Sartorius 25 Jul 2011

Sigma Life Science releases breast cancer-specific knockout and knockin cell lines for drug research

Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich, today announced the expansion of its CompoZr® Oncology Disease Model portfolio with the release of the first in its collection of breast cancer-specific knockout and knockin cell lines for drug discovery and research.

22 Jul 2011

SG Austria acquisition benefits Nuvilex with $1.5M in grant funding

Nuvilex, Inc. announced today that as part of its acquisition of SG Austria, Nuvilex will benefit from grant funding previously awarded to SG Austria for its live-cell encapsulation activities and other projects. The total grant funding awarded to SG Austria is approximately $1.5 million.

22 Jul 2011

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.

22 Jul 2011

Enrollment begins in Repligen's RG1068 pilot study to improve detection, staging of pancreatic cancer

Repligen Corporation today announced that the first patient has been enrolled in a pilot study to evaluate the ability of RG1068 to improve detection and characterization of pancreatic cancer in combination with contrast-enhanced magnetic resonance imaging (MRI) and computed tomography.

22 Jul 2011

UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV

UK regulators have approved Europe's first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.

22 Jul 2011

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

Biotechnology News and Research

Daiichi Sankyo to deploy Veeva CRM for strengthening customer engagements in the UK

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

UC San Diego receives NHLBI 'Program of Excellence in Glycosciences' grant

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Advanced Instruments launches Advanced Automated Osmometer

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

New WHO policy recommendation warns against use of blood tests for active TB

Sartorius sales revenue increases 12.2% to 353.7M euros in the first half of 2011

Sigma Life Science releases breast cancer-specific knockout and knockin cell lines for drug research

SG Austria acquisition benefits Nuvilex with $1.5M in grant funding

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

Enrollment begins in Repligen's RG1068 pilot study to improve detection, staging of pancreatic cancer

UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV

Quest receives U.S. patent allowance for cancer combination therapy

FDA approves Cephalon's REMS for FENTORA, ACTIQ

A*STAR's ETC, Agilent introduce drug screening platform

Baxter net income increases 15% to $615 million for second quarter 2011

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News